论文部分内容阅读
目的:探析多种肿瘤标志物联合检测对乳腺癌患者诊断的临床意义。方法:分析2013年11月~2015年8月在我院接受治疗的77例乳腺癌患者的临床资料。另外选取同期在我院接受治疗的51例乳腺良性患者作为本实验的乳腺良性组、接受健康体检的63名健康女性作为本次实验的对照组。采用化学发光微粒子免疫分析(CMIA)法检测三组患者的血清糖类抗原(CA)153、CA125以及癌胚抗原(CEA)的表达水平。比较三组患者的一般资料以及血清CA125、CA153、CEA检测结果。比较单项检测与多项指标联合检测的敏感性与特异性。结果:乳腺癌组患者的血清CA125、CA153和CEA水平均明显比乳腺良性组、对照组高;乳腺良性组患者的血清CA125、CA153及CEA水平与对照组间无明显差异。与单项肿瘤标志物相比,多项指标联合检测的敏感性(69.1%)和准确度(85.7%)最高。结论:血清CA125、CA153及CEA的联合检测可以显著提升乳腺癌的早期检出率以及诊断性能,在鉴别诊断乳腺癌及其良性病变方面具有重要的临床意义。
Objective: To explore the clinical significance of combined detection of multiple tumor markers in the diagnosis of breast cancer patients. Methods: The clinical data of 77 breast cancer patients treated in our hospital from November 2013 to August 2015 were analyzed. In addition, we selected 51 benign breast patients receiving treatment in our hospital as the benign breast group and 63 healthy women undergoing physical examination as the control group. The levels of serum carbohydrate antigen (CA) 153, CA125 and carcinoembryonic antigen (CEA) in three groups were detected by chemiluminescence microparticle immunoassay (CMIA). The general data of three groups were compared with the results of serum CA125, CA153 and CEA. Compare the sensitivity and specificity of the combined detection of single test and multiple indicators. Results: Serum levels of CA125, CA153 and CEA in patients with breast cancer were significantly higher than those in benign and benign breast tissues. There was no significant difference in serum CA125, CA153 and CEA levels between patients with benign breast disease and control group. The sensitivity (69.1%) and accuracy (85.7%) of the combined detection of multiple indicators were the highest compared with the single tumor markers. Conclusion: The combined detection of serum CA125, CA153 and CEA can significantly improve the early detection rate and diagnostic performance of breast cancer, which has important clinical significance in the differential diagnosis of breast cancer and its benign lesions.